FDA Clearance Tracker · P150021
FREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM
Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Sep 23, 2016
Approved
Time to decision
462 days
Received Jun 19, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P150021
- Device name
- FREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM
- Applicant
- Abbott Diabetes Care, Inc.
- Applicant location
- Alameda, CA
- Received
- Jun 19, 2015
- Decided
- Sep 23, 2016
- Decision
- Approved
- Supplements
- 59 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The System is intended for use by health care professionals and requires a prescription. Readings from the FreeStyle Libre Pro Sensor are only made available to patients through consultation with a health care professional. The System does not require user calibration with blood glucose values.The FreeStyle Libre Pro System aids in the detection of glucose level excursions above or below the desired range, facilitating therapy adjustments. Interpretation of the FreeStyle Libre Pro Flash Glucose Monitoring System readings should be based on the trends and patterns analyzed through time using the reports available.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MDS. The earliest in FDA's data is P980022, decided Jun 15, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K233537 · Decided Apr 23, 2024 · 172 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K223435 · Decided Apr 13, 2023 · 150 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K222447 · Decided Mar 3, 2023 · 200 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.